cancer-biology
Can CRC tumor microenvironments be sorted into useful subtypes?
Open access · cc by · source: Europe PMC
Multi-omics CCCRC typing splits colorectal cancers into proliferative (C1), immunosuppressed (C2), immune-excluded (C3), and immunomodulatory (C4) TME classes with different therapy leads.
Study at a glance
- Design
- Computational / modelling — Integrative multi-omics + AI spatial WSI analysis defining CCCRC TME subtypes
- N
- N=1471 · 1471 CRC patients in CRC-AFFY cohort heatmap; 725 in CRC-RNAseq cohort
- Population
- Colorectal cancer bulk/multi-omics cohorts with TME signature profiling
- Outcome
- Four CCCRC TME subtypes with distinct therapy/prognosis implications
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
C1 is proliferative/low immunogenicity (chemo + cetuximab candidate); C2 is immunosuppressed/terminally exhausted (chemo + bevacizumab candidate); C3 is stromal/immune-excluded (WNT inhibitor WIKI4 sensitivity); C4 is immunomodulatory (immune checkpoint blockade candidate).
Methodology
Built a 61-signature TME panel, integrated multi-omics CRC cohorts, and used AI-enabled spatial whole-slide analysis to define CCCRC subtypes, then linked subtypes to histology, molecular features, treatment sensitivity, prognosis, and a simple gene classifier.
Limitations
Subtype–therapy matches are hypothesis-generating from observational/computational data, not randomized treatment trials.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.